Polypharmacy and specific comorbidities in university primary care settings

European Journal of Internal Medicine

Volumn 35, Issue , 2016, Pages 35-42

  Aubert, Carole E ^a   Streit, Sven ^b   Da Costa, Bruno R ^b   Collet, Tinh Hai ^c,d   Cornuz, Jacques ^e   Gaspoz, Jean Michel ^f   Bauer, Doug ^g   Aujesky, Drahomir ^a   Rodondi, Nicolas ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Comorbidities; Inappropriate prescribing; Multimorbidity; Pharmacoepidemiology; Polypharmacy

Indexed keywords

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYPHARMACY; POTENTIAL PRESCRIBING OMISSION; PREVALENCE; PRIMARY MEDICAL CARE; UNIVERSITY HOSPITAL; VERY ELDERLY; CARDIOVASCULAR DISEASES; FACTUAL DATABASE; MULTIVARIATE ANALYSIS; PRIMARY HEALTH CARE; RENAL INSUFFICIENCY, CHRONIC; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SWITZERLAND;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION; INAPPROPRIATE PRESCRIBING; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYPHARMACY; PRIMARY HEALTH CARE; RENAL INSUFFICIENCY, CHRONIC; SWITZERLAND;

EID: 84997502438     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2016.05.022     Document Type: Article

References (54)

1. [1] World Health Organisation, WHO methods for life expectancy and healthy life expectancy. Global health estimates technical paper WHO/HIS/HSI/GHE/2014.5, March 2014.
2. [2] Rizza, A., et al. Age- and gender-related prevalence of multimorbidity in primary care: the Swiss FIRE project. BMC Fam Pract, 13, 2012, 113.
3. [3] Barnett, K., et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380:9836 (2012), 37–43.
4. [4] Nishtala, P.S., Salahudeen, M.S., Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005-2013. Gerontology 61:3 (2015), 195–202.
5. [5] Boyd, C.M., et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294:6 (2005), 716–724.
6. [6] Westin, S., Heath, I., Thresholds for normal blood pressure and serum cholesterol. BMJ 330:7506 (2005), 1461–1462.
7. [7] Silwer, L., Lundborg, C.S., Patterns of drug use during a 15 year period: data from a Swedish county, 1988–2002. Pharmacoepidemiol Drug Saf 14:11 (2005), 813–820.
8. [8] Anthierens, S., et al. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract, 11, 2010, 65.
9. [9] Hovstadius, B., et al. Increasing polypharmacy — an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol, 10, 2010, 16.
10. [10] Guthrie, B., et al. The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995-2010. BMC Med, 13, 2015, 74.
11. [11] Haider, S.I., et al. Trends in polypharmacy and potential drug–drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther 45:12 (2007), 643–653.
12. [12] Gnjidic, D., et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65:9 (2012), 989–995.
13. [13] Payne, R.A., et al. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol 70:5 (2014), 575–581.
14. [14] Qato, D.M., et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:24 (2008), 2867–2878.
15. [15] Scott, I.A., et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 175:5 (2015), 827–834.
16. [16] Ahmed, B., et al. Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in Karachi: a prospective cohort study. PLoS One, 9(11), 2014, e112133.
17. [17] Jyrkka, J., et al. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 26:12 (2009), 1039–1048.
18. [18] Beer, C., et al. Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study. Br J Clin Pharmacol 71:4 (2011), 592–599.
19. [19] Payne, R.A., et al. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol 77:6 (2014), 1073–1082.
20. [20] Goldberg, R.M., et al. Drug–drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14:5 (1996), 447–450.
21. [21] Tommelein, E., et al. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol 71:12 (2015), 1415–1427.
22. [22] Franchi, C., et al. Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-elderly project 2000-2010. Eur J Clin Pharmacol 70:4 (2014), 437–443.
23. [23] Gallagher, P., et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol 67:11 (2011), 1175–1188.
24. [24] Lang, P.O., et al. Potentially inappropriate prescribing including under-use amongst older patients with cognitive or psychiatric co-morbidities. Age Ageing 39:3 (2010), 373–381.
25. [25] Collet, T.H., et al. The quality of primary care in a country with universal health care coverage. J Gen Intern Med 26:7 (2011), 724–730.
26. [26] Blozik, E., et al. Polypharmacy and potentially inappropriate medication in the adult, community-dwelling population in Switzerland. Drugs Aging 30:7 (2013), 561–568.
27. [27] Leiss, W., et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med 30:1 (2015), 17–24.
28. [28] Aarts, S., et al. The effect of multimorbidity on health related functioning: temporary or persistent? Results from a longitudinal cohort study. J Psychosom Res 73:3 (2012), 211–217.
29. [29] Fortin, M., et al. Prevalence estimates of multimorbidity: a comparative study of two sources. BMC Health Serv Res, 10, 2010, 111.
30. [30] van den Bussche, H., et al. Patterns of ambulatory medical care utilization in elderly patients with special reference to chronic diseases and multimorbidity—results from a claims data based observational study in Germany. BMC Geriatr, 11, 2011, 54.
31. [31] Gallacher, K.I., et al. Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden. BMC Med, 12, 2014, 151.
32. [32] Streit, S., et al. Multimorbidity and quality of preventive care in Swiss university primary care cohorts. PLoS One, 9(4), 2014, e96142.
33. [33] Higashi, T., et al. Relationship between number of medical conditions and quality of care. N Engl J Med 356:24 (2007), 2496–2504.
34. [34] Charlson, M.E., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:5 (1987), 373–383.
35. [35] Piette, J.D., et al. Veterans affairs research on health information technologies for diabetes self-management support. J Diabetes Sci Technol 2:1 (2008), 15–23.
36. [36] O'Mahony, D., et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 44:2 (2015), 213–218.
37. [37] Jadad, A.R., et al. Consideration of multiple chronic diseases in randomized controlled trials. JAMA 306:24 (2011), 2670–2672.
38. [38] Guthrie, B., et al. Adapting clinical guidelines to take account of multimorbidity. BMJ, 345, 2012, e6341.
39. [39] Beers, M.H., et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA division of geriatric medicine. Arch Intern Med 151:9 (1991), 1825–1832.
40. [40] Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK prospective diabetes study group. BMJ, 317(7160), 1998, 720–726.
41. [41] Williams, B., et al. Guidelines for management of hypertension: report of the fourth working party of the British hypertension society, 2004-BHS IV. J Hum Hypertens 18:3 (2004), 139–185.
42. [42] Yang, M., et al. Does residing in urban or rural areas affect the incidence of polypharmacy among older adults in western China?. Arch Gerontol Geriatr 60:2 (2015), 328–333.
43. [43] Corsonello, A., et al. Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag 3:1 (2007), 197–203.
44. [44] Diez-Manglano, J., et al. Polypharmacy in patients hospitalised for acute exacerbation of COPD. Eur Respir J 44:3 (2014), 791–794.
45. [45] Nobili, A., et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol 67:5 (2011), 507–519.
46. [46] Correll, C.U., Gallego, J.A., Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am 35:3 (2012), 661–681.
47. [47] Hongisto, K., V.S., Martikainen, J., Hallikainen, I., Välimäki, T., Hartikainen, S., et al. Self-rated and caregiver-rated quality of life in Alzheimer disease with a focus on evolving patient ability to respond to questionnaires: 5-year prospective ALSOVA cohort study. Am J Geriatr Psychiatry, 2015 [S1064–7481(15)00206–7].
48. [48] LeBlanc, T.W., et al. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol 16:7 (2015), e333–e341.
49. [49] Mayer, S., Osterle, A., Socioeconomic determinants of prescribed and non-prescribed medicine consumption in Austria. 2014, Eur J Public Health.
50. [50] Jacquin-Piques, A., et al. Psychotropic drug prescription in patients with dementia: nursing home residents versus patients living at home. J Alzheimers Dis 49:3 (2015), 671–680.
51. [51] Jokanovic, N., et al. Why is polypharmacy increasing in aged care facilities? The views of Australian health care professionals. J Eval Clin Pract, 2016.
52. [52] Onder, G., et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci 67:6 (2012), 698–704.
53. [53] Peabody, J.W., et al. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA 283:13 (2000), 1715–1722.
54. [54] Sharifi, H., Hasanloei, M.A., Mahmoudi, J., Polypharmacy-induced drug–drug interactions; threats to patient safety. Drug Res (Stuttg) 64:12 (2014), 633–637.